BioSpace News Archive

Business

Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space

Psycheceutical Bioscience, Inc. appointed Neilank K. Jha, MD, Executive Chairman and CEO on November 1, 2023 to initiate an immediate turnaround to avert restructuring for operational, financial and regulatory reasons.

January 17, 2024
·
6 min read
Deals

Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

Myomo, Inc. today announced that it has entered into securities purchase agreements with certain new and existing institutional investors as well as certain insiders of the Company for the purchase and sale of 1,578,948 shares of common stock.

January 17, 2024
·
6 min read
Biotech Bay

Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence

Guardant Health, Inc. will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium, January 18-20 in San Francisco.

January 17, 2024
·
5 min read
Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. (NYSE: FNA), is excited to announce the limited market release of its Bun-Yo-Matic™ Lapidus Clamp System and completion of the first surgical cases in Orange County, California and Seattle, Washington.

January 17, 2024
·
5 min read
Business

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

UroGen Pharma Ltd. today announced a licensing agreement with medac GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers.

January 17, 2024
·
6 min read
Business

Allosteric Bioscience, Inc. Signs Sponsored Research Agreement with Dr. Susan Michaelis at Johns Hopkins University for Aging/Longevity-Related Work

Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.

January 17, 2024
·
3 min read
BioMidwest

Vergent Bioscience to Present New Efficacy Results from Phase 2 Clinical Trial of VGT-309 at Annual Meeting of The Society of Thoracic Surgeons

Vergent Bioscience announced that new results from the Phase 2 clinical program evaluating the company’s investigational agent VGT-309 will be presented at STS 2024, the 60th Annual Meeting of Thoracic Surgeons, taking place January 27-29, 2024, in San Antonio, Texas.

January 17, 2024
·
3 min read
Biotech Beach

Thermo Fisher Scientific Unveils Industry’s First Off-the-Shelf Validated Software Solution to Automate Cell Therapy Manufacturing Workflows

Thermo Fisher Scientific today announced the launch of the Gibco™ Cell Therapy Systems (CTS™) Cellmation™ Software , a first-of-its-kind automation solution designed to connect and integrate workflows across multiple Thermo Fisher Scientific cell therapy instruments while enabling cGMP compliance.

January 17, 2024
·
3 min read
Business

Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)

Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD).

January 17, 2024
·
4 min read
Drug Development

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors.

January 17, 2024
·
8 min read